Clinical research company Medpace Holdings (NASDAQ: MEDP) will be announcing earnings results this Monday afternoon. Here’s what to expect.
Medpace beat analysts’ revenue expectations by 2.7% last quarter, reporting revenues of $659.9 million, up 23.7% year on year. It was an exceptional quarter for the company, with a solid beat of analysts’ organic revenue estimates and a solid beat of analysts’ full-year EPS guidance estimates.
Is Medpace a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Medpace’s revenue to grow 27.9% year on year to $686.1 million, improving from the 7.7% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $4.23 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Medpace has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Medpace’s peers in the life sciences tools & services segment, some have already reported their Q4 results, giving us a hint as to what we can expect. IQVIA delivered year-on-year revenue growth of 10.3%, beating analysts’ expectations by 2.9%, and Azenta reported flat revenue, topping estimates by 1.1%. IQVIA traded down 7.4% following the results while Azenta was also down 24.5%.
Read our full analysis of IQVIA’s results here and Azenta’s results here.
The outlook for 2025 remains clouded by potential trade policy changes and corporate tax discussions, which could impact business confidence and growth. While some of the life sciences tools & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.2% on average over the last month. Medpace is down 8.3% during the same time and is heading into earnings with an average analyst price target of $545.75 (compared to the current share price of $542.54).
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
